Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Recent News

ASCO 2021: Time-Limited Use of Aspacytarabine for Patients With AML Who Are Unfit for Chemotherapy
EHA2021: Post Hoc Analysis of Oral Azacitidine in AML From QUAZAR AML-001 Trial
ASCO 2021: Novel FLT3 Inhibitor Under Study in Resistant AML
ASCO 2021: Interim Analysis of Phase II Trial of Olutasidenib in IDH1-Mutant AML
Australian Researchers Use Novel Work Utility Measure to Assess Productivity Impact of AML
Trousseau Syndrome and AML: Case Report
Venetoclax-Based Therapy and Azole Antifungals in AML: Effects on Blood Cell Counts
Quizartinib Combinations Under Study in FLT3-ITD–Mutated AML
Whole-Genome Sequencing for Genetic Profiling in Myeloid Cancers
Pilot Study in AML: Can Biomarkers Predict Chemotherapy-Related Infection?
Dactinomycin Under Study in Management of Resistant NPM1-Mutated AML
Have Outcomes in AML Improved Over the Past 40 Years?
CPX-351 for High-Risk AML: Phase III Post Hoc Analysis
AACR 2021: Daratumumab Plus Venetoclax Under Study in AML
Chemotherapy Intensity, MRD Status, and Outcomes in AML
AACR 2021: Is SIRT5 Enzyme Potential Therapeutic Target in AML?
Optimal Number of Chemotherapy Courses for Younger Patients With AML
Testing for Germline Mutations in Elderly Patients With AML
Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML
Comparison of Hypomethylating Agent Plus Venetoclax With CPX-351 in Secondary AML
Predicting Response to Venetoclax Combination Therapy in Resistant AML
Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML
Case Report: Central Diabetes Insipidus and AML
Using Existing Drugs to Treat Unique Subtype of NPM1-Mutated AML
Phase II French Trial of Eprenetapopt Plus Azacitidine in AML
Prognostic Impact of IDH Mutational Status in AML After HSCT
Can Fractionated Myeloablative Busulfan Regimen Improve Outcomes in Older Patients With AML?
Could AML Progression Be Fueled by Chemotherapy-Induced Dormancy of AML Cells?
Is MRD Status Predictive of Survival in Resistant AML?
Association Between Pretransplant Molecular MRD and Outcomes in AML
Novel Combination Results in Anticancer ‘Double Whammy’ in AML
TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML
TCT 2021: CPX-351 Versus Chemotherapy for High-Risk of Secondary AML
TCT 2021: Effects of HSCT After Azacitidine Therapy for AML
Does Exposure to Occupational Pesticides Increase the Risk for AML?
TCT 2021: JSP191 With Fludarabine and Total-Body Radiation in Older Adults With AML
Eprenetapopt Plus Azacitidine Under Study in TP53-Mutant AML
Decitabine Plus Venetoclax Versus Chemotherapy Among Older Patients With AML
Why Do Some Patients With Newly Diagnosed AML Decline Treatment?
Newly Diagnosed FLT3-Mutant AML: Sorafenib Plus Chemotherapy
Gilteritinib Plus Chemotherapy for Newly Diagnosed AML
Intravenous and Subcutaneous Cytarabine for Standard Induction Therapy in AML
Quizartinib-Based Triplet Therapy for FLT3-ITD–Mutated AML
5-Year Results for CPX-351 in Older Adults With High-Risk AML
Safety Profile of Midostaurin in Older Patients With AML
Oral Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia
Race Matters Significantly in AML Outcomes, Study Data Show
ASH 2020: Phase III Trial of Gilteritinib Plus Azacitidine for FLT3-Mutated AML


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.